Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
28,862,345
-
Total 13F shares
-
20,231,748
-
Share change
-
+662,327
-
Total reported value
-
$956,338,910
-
Put/Call ratio
-
10%
-
Price per share
-
$47.27
-
Number of holders
-
149
-
Value change
-
+$17,270,558
-
Number of buys
-
65
-
Number of sells
-
75
Institutional Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q2 2022
As of 30 Jun 2022,
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) was held by
149 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,231,748 shares.
The largest 10 holders included
BlackRock Inc., ARMISTICE CAPITAL, LLC, STATE STREET CORP, FARALLON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, NORTHERN TRUST CORP, RA CAPITAL MANAGEMENT, L.P., Krensavage Asset Management, LLC, RENAISSANCE TECHNOLOGIES LLC, and DIMENSIONAL FUND ADVISORS LP.
This page lists
149
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.